BioNTech SE (BNTX)
100.75
5.37 (5.63%)
At close: Mar 24, 2025, 3:59 PM
100.50
-0.25%
After-hours: Mar 24, 2025, 07:59 PM EDT
5.63% (1D)
Bid | 98 |
Market Cap | 24.18B |
Revenue (ttm) | 2.73B |
Net Income (ttm) | -673.02M |
EPS (ttm) | -3.02 |
PE Ratio (ttm) | -33.36 |
Forward PE | -36.66 |
Analyst | Buy |
Ask | 100.61 |
Volume | 863,952 |
Avg. Volume (20D) | 765,239 |
Open | 95.65 |
Previous Close | 95.38 |
Day's Range | 95.65 - 100.98 |
52-Week Range | 76.53 - 131.49 |
Beta | 0.31 |
About BNTX
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for tripl...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 10, 2019
Employees 6,772
Stock Exchange NASDAQ
Ticker Symbol BNTX
Website https://www.biontech.de
Analyst Forecast
According to 16 analyst ratings, the average rating for BNTX stock is "Buy." The 12-month stock price forecast is $144, which is an increase of 42.92% from the latest price.
Stock Forecasts2 weeks ago
-6.61%
BioNTech shares are trading lower. Morgan Stanley ...
Unlock content with
Pro Subscription
2 weeks ago
-3.15%
BioNTech SE shares are trading lower. The company reported Q4 financial results.